BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 963 | Download: 769
Publication Name World Journal of Clinical Oncology
Manuscript ID 8734
Country Denmark
Received
2014-01-04 14:24
Peer-Review Started
2014-01-04 19:26
To Make the First Decision
2014-02-13 16:04
Return for Revision
2014-02-20 20:38
Revised
2014-03-10 21:40
Second Decision
2014-06-16 13:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-16 14:06
Articles in Press
2014-06-16 14:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-24 14:16
Publish the Manuscript Online
2014-08-01 16:16
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Biology
Manuscript Type Topic Highlights
Article Title C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma
Manuscript Source Invited Manuscript
All Author List Benedikte Jacobsen, Mette Camilla Kriegbaum, Eric Santoni-Rugiu and Michael Ploug
Funding Agency and Grant Number
Funding Agency Grant Number
Copenhagen University Hospital (Rigshospitalets Forskningspuljer)
he Danish National Research Foundation (Danish-Chinese Centre for Proteases and Cancer)
Harboefonden, Torben og Alice Frimodts Fond
Fabrikant Einar Willumsens Mindelegat
Holger Rabitz and hustrus Legat
Lundbeck Foundation
Corresponding Author Michael Ploug, PhD, DSc, The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maal?es Vej 5, Room 3.3.31, 2200 Copenhagen, Denmark. m-ploug@finsenlab.dk
Key Words LYPD3; Non-small cell lung cancer; Prognosis; Solid growth pattern; Liver kinase B1; Precursor lesions; Atypical adenomatous hyperplasia; Metaplasia; Squamous differentiation; Ly6/Urokinase-type plasminogen activator receptor
Core Tip C4.4A is a new biomarker with potential prognostic value in pulmonary adenocarcinoma. High levels of protein expression correlate with poor patient survival and a histological growth pattern of the solid type. Recent data suggest that C4.4A is negatively regulated by the tumor suppressor liver kinase B1 (LKB1), which is inactivated in a fraction of adenocarcinomas of the lung. Such an inverse association between C4.4A and LKB1 could possibly render C4.4A a candidate predictive biomarker for therapeutic intervention targeting components of the LKB1 pathway, such as mammalian target of rapamycin.
Publish Date 2014-08-01 16:16
Citation Jacobsen B, Kriegbaum MC, Santoni-Rugiu E, Ploug M. C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma. World J Clin Oncol 2014; 5(4): 621-632
URL http://www.wjgnet.com/2218-4333/full/v5/i4/621.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i4.621
Full Article (PDF) WJCO-5-621.pdf
Full Article (Word) WJCO-5-621.doc
Manuscript File 8734-Review.doc
Answering Reviewers 8734-Answering reviewers.pdf
Copyright License Agreement 8734-Copyright assignment.pdf
Peer-review Report 8734-Peer review(s).pdf
Scientific Misconduct Check 8734-CrossCheck.jpg
Scientific Editor Work List 8734-Scientific editor work list.pdf